Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
August 09, 2022 07:00 ET
|
Cogent Biosciences, Inc.
On-track to present additional data from Phase 2 APEX trial by the end of 2022 Initial data from Phase 2 SUMMIT trial & lead-in data from Phase 3 PEAK trial planned for 1H23 Ended 2Q 2022...
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 16, 2022 16:01 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants
June 13, 2022 21:48 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Proposed Public Offering of Common Stock
June 13, 2022 06:00 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
June 10, 2022 07:00 ET
|
Cogent Biosciences, Inc.
All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment All bone marrow biopsy-assessed...
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
June 06, 2022 10:15 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., June 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Annual Meeting of Stockholders
June 02, 2022 08:00 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
May 12, 2022 10:00 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 10, 2022 07:00 ET
|
Cogent Biosciences, Inc.
Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential best-in-class...
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
May 06, 2022 08:00 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...